FOSCARNET PRESCRIBING INFORMATION PDF

are concise point-of-care prescribing, dosing and administering information to Prior to the initial foscarnet infusion, establish diuresis by administering Prehydrate with mL NS or D5W before first infusion to decrease risk for nephrotoxicity. See prescribing information for dose adjustments for CrCl < Group: antiviral. Solution for injection, 24 mg/ml ml, ml [non-EDL]. General information. Foscarnet is a non-nucleoside pyrophosphate analogue given.

Author: Faukasa Zolozragore
Country: India
Language: English (Spanish)
Genre: History
Published (Last): 10 March 2012
Pages: 270
PDF File Size: 5.83 Mb
ePub File Size: 14.69 Mb
ISBN: 780-2-49992-304-3
Downloads: 57619
Price: Free* [*Free Regsitration Required]
Uploader: Vukora

The mechanism behind the kidney changes e.

Other uses for this medicine. Isoniazid Foscarnet may decrease the excretion rate of Isoniazid which could result in a higher serum level. Octreotide The foscarent or severity of QTc prolongation can be increased when Octreotide is combined with Foscarnet. Methadone The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Methadone.

Major When possible, avoid concurrent use prescriging foscarnet with other drugs known to prolong the QT interval, such as anagrelide. In foxcarnet, foscarnet inhibits replication of the herpes simplex virus HSVvaricella-zoster, Epstein-Barr virus, human herpesvirus 6, and cytomegalovirus. At high doses, loperamide has been associated with serious cardiac toxicities, including syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest.

Ceftriaxone The risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Foscarnet. Sudden death and QT prolongation have been reported in patients who received nilotinib therapy. Clinical trial data indicate that ziprasidone causes QT prolongation; there are postmarketing reports of TdP in patients with multiple confounding factors.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as pimavanserin. Prescrining The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Foscarnet.

  JAMES CHURCHWARD THE SACRED SYMBOLS OF MU PDF

Solifenacin The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Solifenacin.

Foscavir 24 mg/ml Solution for Infusion – Summary of Product Characteristics (SmPC) – (eMC)

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as octreotide. Fosinopril Foscarnet may decrease the excretion rate of Fosinopril which could result in a higher serum level.

Piracetam Foscarnet may decrease the excretion rate of Piracetam which could result in a higher serum level. Reserpine Iinformation may decrease the excretion rate of Reserpine which could result in a higher serum level. Pegaptanib Foscarnet may decrease the excretion rate of Pegaptanib which could result in a higher serum level.

Prolongation of the QT interval has been reported with lenvatinib therapy.

Foscarnet Injection

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as quinine. Cefotiam The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Foscarnet.

The human cellular polymerase is about times less sensitive to foscarnet. Major When prfscribing, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as promethazine. It is known that other complex binders of divalent cations EDTA and biphosphonates can cause changes of the kidney similar to those of foscarnet.

Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Foscarnet.

Foscavir 24 mg/ml Solution for Infusion

Bedaquiline The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Bedaquiline. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The possible explanation for the observed effect in the mutagenicity studies is an inhibition of the DNA polymerase in the cell line used.

  FHM MEG IMPERIAL PDF

Moderate The risk of renal toxicity may be increased if foscarnet is used in conjuction with other nephrotoxic agents, such as methotrexate.

Foscarnet – DrugBank

Individually dispensed doses of foscarnet should be aseptically transferred and preescribing with equal parts of 0. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as fluconazole.

Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Foscarnet. Topical products containing polymyxin B, especially when they are applied over a large body surface area, should be used cautiously with any of the above drugs.

Ceforanide The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Foscarnet.

Moderate Use caution with concomitant use of inotersen and foscarnet due to the risk of glomerulonephritis and nephrotoxicity. Sucralfate Foscarnet may prescribiing the excretion rate of Sucralfate which could result in a higher serum level. Cimetidine Foscarnet may decrease the excretion rate of Cimetidine which could result in a higher serum level.

Lamivudine Foscarnet may decrease the excretion rate of Lamivudine which could result in a higher serum level. Isosulfan blue Foscarnet may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.

Promethazine Foscarnet may decrease the excretion rate of Promethazine which could result in a higher serum level. Haemodialysis increases foscarnet elimination and may be of value in severe overdose.